8-K: Galectin Reports 2025 Results, Belapectin Progress, Cash Runway

Galectin Therapeutics announced its 2025 financial results, highlighted progress in its belapectin development program for MASH cirrhosis, and extended its cash runway through April 2027.

Summary

• Galectin Therapeutics reported financial results for the year ended December 31, 2025, and provided a business update.
• Meaningful progress was made in advancing the belapectin program for MASH cirrhosis and portal hypertension, with encouraging signals observed from the NAVIGATE dataset, including additional biomarkers.
• The company secured an additional $10 million line of credit from its Chairman, Dick Uihlein, extending the projected cash runway through April 2027.
• Dr. Henry Brem, an internationally recognized neurosurgeon-scientist, was appointed to the Board, strengthening clinical development expertise.
• In the NAVIGATE Phase 2b/3 trial, belapectin 2 mg/kg reduced the incidence of varices by 49.3% versus placebo in the per-protocol population (nominal p = 0.04).
• In U.S. patients within the per-protocol population, belapectin 2 mg/kg reduced the incidence of varices by 68.1% compared with placebo (p = 0.02).
• Safety results showed a similar proportion of treatment-emergent adverse events, serious adverse events, and discontinuations across treatment groups, with no drug-related serious adverse events observed.
• Additional 18-month NAVIGATE biomarker analyses demonstrated consistent effects across multiple non-invasive markers of fibrosis and disease progression (FibroScan liver stiffness, ELF score, PRO-C3, YKL-40, PRO-C4), supporting belapectin's potential antifibrotic and disease-modifying activity.
• Analyses using validated Baveno VII criteria suggested belapectin treatment was associated with improvements in portal hypertension risk categories and a reduced risk of hepatic decompensation.
• Net loss applicable to common stockholders for 2025 was $31.0 million, or ($0.48) per share, a decrease from $47.2 million, or ($0.76) per share, in 2024.
• Research and development expenses decreased to $14.3 million in 2025 from $36.6 million in 2024, primarily due to the conclusion of the NAVIGATE clinical trial.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, primarily driven by the encouraging clinical signals for belapectin in a high-need area and improved financial runway, despite the ITT population not reaching statistical significance.

Positives

• Belapectin 2 mg/kg demonstrated a 49.3% reduction in varices incidence in the per-protocol population (nominal p = 0.04) and a 68.1% reduction in U.S. per-protocol patients (p = 0.02).
• Consistent positive signals were observed across multiple non-invasive markers of fibrosis and disease progression (FibroScan, ELF score, PRO-C3, YKL-40, PRO-C4), supporting belapectin's potential antifibrotic and disease-modifying activity.
• Analyses using Baveno VII criteria suggested belapectin treatment was associated with improvements in portal hypertension risk categories and a reduced risk of hepatic decompensation.
• The company's cash runway was extended through April 2027 due to a new $10 million line of credit from its Chairman.
• Net loss decreased significantly to $31.0 million in 2025 from $47.2 million in 2024.
• Research and development expenses decreased substantially to $14.3 million in 2025 from $36.6 million in 2024, primarily due to the conclusion of the NAVIGATE trial.
• The Board was strengthened with the appointment of Dr. Henry Brem, an internationally recognized neurosurgeon-scientist with valuable clinical development experience.
• Multiple abstracts from the NAVIGATE program have been accepted for presentations at the upcoming EASL Congress, including one oral presentation, reflecting continued scientific interest.

Negatives

• In the intent-to-treat population (n=355), the composite endpoint for varices incidence did not reach statistical significance, despite a 43.2% lower incidence in patients treated with belapectin 2 mg/kg.
• The company continues to incur significant operating losses, reporting a net loss of $31.0 million in 2025.
• Advancement of additional clinical programs, such as cancer immunotherapy, is largely dependent on finding a suitable partner.
• Total stockholders' equity remains a significant deficit at $(127.9) million as of December 31, 2025.

Risks

• Full analysis of the NAVIGATE trial data may not produce positive data.
• Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development.
• The Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters.
• Current clinical trials and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time-consuming and costly.
• Plans regarding development, approval, and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies.
• Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials.
• Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations.

Future Outlook

The company plans an FDA meeting in the second quarter of 2026 to align on the next steps for advancing the belapectin program. New NAVIGATE trial analyses, including an oral presentation on reduced varices based on favorable changes in markers of fibrosis formation and resolution, and a poster presentation on risk reduction in clinically significant portal hypertension, will be presented at EASL 2026 (May 27-30, 2026). The company believes belapectin has the potential to address a significant unmet medical need in MASH cirrhosis, for which there are currently no approved therapies.

Management Comments

• "We are at an important juncture for the belapectin development program." Joel Lewis, Chief Executive Officer and President
• "We are encouraged by the signals observed, including additional biomarkers from the NAVIGATE dataset, and remain focused on evaluating the data as we engage with regulators, potential partners, and leading experts to determine the optimal path forward for the program." Joel Lewis, Chief Executive Officer and President
• "Importantly, we also improved the Company's financial position during the year, including securing an additional $10 million line of credit from our Chairman, Dick Uihlein, to extend our projected cash runway through April 2027." Joel Lewis, Chief Executive Officer and President
• "With no approved therapies currently available for patients with MASH cirrhosis, we believe belapectin has the potential to address a significant unmet medical need and look forward to discussing the program with FDA." Joel Lewis, Chief Executive Officer and President
• "The NAVIGATE dataset continues to provide encouraging insights supporting belapectin's potential role in patients with MASH cirrhosis and portal hypertension." Khurram Jamil, M.D., Chief Medical Officer
• "We are excited about our upcoming FDA meeting in the second quarter of 2026 to align on the next steps for advancing the program." Khurram Jamil, M.D., Chief Medical Officer

Industry Context

StockSavvy.ai notes that MASH cirrhosis currently has no approved therapies, positioning belapectin to address a significant unmet medical need if its development program proves successful. The continued interest from the scientific community, evidenced by multiple accepted abstracts for the upcoming EASL Congress, suggests the data is compelling and relevant within the hepatology field, potentially differentiating belapectin in a crowded MASH development landscape.

Comparison to Industry Standards

• The NAVIGATE trial results, particularly the 49.3% reduction in varices incidence in the per-protocol population and 68.1% reduction in U.S. per-protocol patients, are significant given the lack of approved therapies for MASH cirrhosis, a condition with high morbidity and mortality.
• The consistent positive signals across multiple non-invasive markers of fibrosis (FibroScan, ELF score, PRO-C3) and inflammation (YKL-40, PRO-C4) are crucial for demonstrating disease-modifying effects, a key challenge in MASH drug development, and align with the growing industry focus on comprehensive biomarker responses.
• The Baveno VII criteria analysis suggesting improvements in portal hypertension risk categories is a strong indicator of clinical benefit, as portal hypertension is a major driver of complications in cirrhosis, and few experimental therapies have shown such direct impact on this critical endpoint.
• Compared to other MASH drug candidates, belapectin's focus on varices prevention and portal hypertension in cirrhotic patients targets a very advanced and high-need population, differentiating it from many earlier-stage MASH therapies primarily focused on fibrosis reduction in non-cirrhotic patients, such as those from companies like Madrigal Pharmaceuticals (resmetirom) or Intercept Pharmaceuticals (obeticholic acid) which target different stages or mechanisms.

Management Changes

Related Party Transactions

• Secured an additional $10 million line of credit from Chairman, Dick Uihlein.

Stakeholder Impact

• Shareholders: Potential for increased value if belapectin progresses successfully through regulatory pathways and partnerships. Reduced net loss and extended cash runway provide some financial stability, but continued operating losses and reliance on future capital raises or partnerships pose risks.
• Patients with MASH cirrhosis: Potential for a much-needed therapy if belapectin proves effective and gains approval, addressing a significant unmet medical need.
• Employees: Continued employment and focus on advancing the belapectin program.
• Creditors: The $10 million line of credit from the Chairman indicates continued support and potentially improved short-term liquidity.

Next Steps

• Engage with regulators, potential partners, and leading experts to determine the optimal path forward for the belapectin program.
• Hold an FDA meeting in the second quarter of 2026 to align on next steps for advancing the program.
• Present new NAVIGATE trial analyses at EASL 2026 (May 27-30, 2026), including an oral presentation on reduced varices and a poster presentation on risk reduction in clinically significant portal hypertension.
• Seek a suitable partner for the advancement of additional clinical programs in cancer immunotherapy and other malignancies.

Key Dates

Recommendation

The clinical data for belapectin, particularly in the per-protocol and U.S. per-protocol populations, shows encouraging signals for a significant unmet medical need in MASH cirrhosis. The extension of the cash runway provides crucial time for the company to engage with regulators and potential partners. However, the lack of statistical significance in the intent-to-treat population and the company's continued reliance on future capital raises or partnerships for broader development introduce considerable risk. A 'hold' recommendation reflects the potential upside from belapectin's progress balanced against the inherent risks of clinical development and the company's financial position.

Keywords

Galectin Therapeutics, GALT, belapectin, MASH cirrhosis, NASH, portal hypertension, NAVIGATE trial, galectin-3 inhibitor, liver disease, fibrosis, clinical trial results, financial results, biotechnology, pharmaceutical, drug development, FDA, EASL